The U.S. Food and Drug Administration (FDA) has recently published several guidance documents and policy updates that clarify and modernize regulatory expectations across digital health, medical devices, real-world evidence, and clinical trial design.
The European Union’s Medical Device Coordination Group (MDCG) has issued two important guidance documents in late 2025, providing clarity and support for stakeholders navigating the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) frameworks.
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly established new AI principles in drug development to reduce regulatory divergence.
The proposed MDR revision marks a turning point for our community, explicitly recognising in silico modelling & simulation as a source of evidence in EU medical device guidance.
The European Commission has published the Horizon Europe Work Programme for 2026 and 2027, setting out the next wave of research and innovation funding under the EU’s flagship programme. The overall programme allocates €14 billion to strategic research and innovation priorities across multiple clusters, including health, digital, industry, climate and more.
The European Partnership for Personalised Medicine, EP PerMed, publishes a funding call for Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026)
The UK government has launched a comprehensive roadmap to accelerate the replacement of animal testing with alternative methods, backed by £75 million in funding.
The 9th wave of calls for proposals under the Digital Europe Programme (Work Programme 2025-2027) was published in October and will be open for submission from 4 November 2025 until 3 March 2026 at 17:00 CET.
We are thrilled to announce that the VPH has been selected as the official Thematic Network for the EU Health Policy Platform under the Virtual Human Twins topic.
